These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 9587050

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H, Mayer PR, Wajdula J, Fatenejad S.
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [Abstract] [Full Text] [Related]

  • 3. Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis.
    Monjanel-Mouterde S, Lafforgue P, Blanc A, Catalin J, Aquaviva PC, Durand A.
    J Rheumatol; 1998 Jul; 25(7):1276-81. PubMed ID: 9676756
    [Abstract] [Full Text] [Related]

  • 4. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
    Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M.
    J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
    [Abstract] [Full Text] [Related]

  • 5. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
    Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M.
    J Rheumatol; 2004 Apr; 31(4):645-8. PubMed ID: 15088287
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients.
    Yukawa E, Mori S, Ueda K, Nakada Y.
    J Clin Pharm Ther; 2007 Dec; 32(6):573-8. PubMed ID: 18021334
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
    Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, Xuan kH, Leblond V, Lechat P.
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
    [Abstract] [Full Text] [Related]

  • 10. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.
    Min Y, Qiang F, Peng L, Zhu Z.
    Biopharm Drug Dispos; 2009 Nov; 30(8):437-47. PubMed ID: 19746402
    [Abstract] [Full Text] [Related]

  • 11. Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics.
    Sabot C, Debord J, Roullet B, Marquet P, Merle L, Lachatre G.
    Int J Clin Pharmacol Ther; 1995 Mar; 33(3):164-9. PubMed ID: 7599915
    [Abstract] [Full Text] [Related]

  • 12. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.
    Bannwarth B, Péhourcq F, Schaeverbeke T, Dehais J.
    Clin Pharmacokinet; 1996 Mar; 30(3):194-210. PubMed ID: 8882301
    [Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetics of methotrexate in the guinea pig.
    Schlatter J, Di Blasi-Bouvet S, Raynaud F, Cisternino S.
    Cell Mol Biol (Noisy-le-grand); 1999 May; 45(3):363-8. PubMed ID: 10386793
    [Abstract] [Full Text] [Related]

  • 14. Comparative studies of quality and bioavailability of methotrexate in Thai patients with rheumatoid arthritis.
    Manorot M, Rojanasathien N, Louthrenoo W, Tonsuwannont W, Teekachunhatean S.
    J Med Assoc Thai; 1998 Dec; 81(12):978-85. PubMed ID: 9916387
    [Abstract] [Full Text] [Related]

  • 15. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
    Vakily M, Amer F, Kukulka MJ, Andhivarothai N.
    J Clin Pharmacol; 2005 Oct; 45(10):1179-86. PubMed ID: 16172183
    [Abstract] [Full Text] [Related]

  • 16. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia.
    Plard C, Bressolle F, Fakhoury M, Zhang D, Yacouben K, Rieutord A, Jacqz-Aigrain E.
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):609-20. PubMed ID: 17195068
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY, Rivory LP, Clarke SJ, McLachlan AJ.
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pendley C, Jiao Q, Shankar G, Marciniak SJ, Cohen SB, Rahman MU, Baker D, Mascelli MA, Davis HM, Everitt DE.
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [Abstract] [Full Text] [Related]

  • 19. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
    Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML.
    Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
    Colom H, Farré R, Soy D, Peraire C, Cendros JM, Pardo N, Torrent M, Domenech J, Mangues MA.
    Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.